2110 results about "Derivatization" patented technology

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38⁺ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

Methods for preparing a biochip are provided herein wherein the biomolecular probe to be used with the biochip is alternatively bound to a hydrogel prepolymer prior to or simultaneously with polymerization of the prepolymer. In particularly preferred embodiments, a polyurethane-based hydrogel prepolymer is derivatized with an organic solvent soluble biomolecule, such as a peptide nucleic acid probe in aprotic, organic solvent. Following derivatization of the prepolymer, an aqueous solution, for example sodium bicarbonate, preferably buffered to a pH of about 7.2 to about 9.5, is added to the derivatized prepolymer solution to initiate polymerization of the hydrogel. Alternatively, a water soluble biomolecule, such as DNA or other oligonucleotide, is prepared in an aqueous solution and added to the polyurethane-based hydrogel prepolymer such that derivatization and polymerization occur, essentially, simultaneously. While the hydrogel is polymerizing, it is microspotted onto a solid substrate, preferably a silanated glass substrate, to which the hydrogel microdroplet becomes covalently bound. Most preferably the hydrogel microdroplets are at least about 30 mum thick, for example about 50 mum to about 100 mum thick. The resulting biochips are particularly useful for gene discovery, gene characterization, functional gene analysis and related studies.

Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

The present invention provides wood derivatives and composite materials prepared by first solvating a lignocellulosic material using an ionic liquid. The solvated lignocellulosic material can be derivatized to incorporate functional groups, particularly groups that facilitate later combination with polymer materials, including non-polymer polymers. The polymeric materials can be combined with the derivatized lignocellulosic material in solution, or the derivatized lignocellulosic material can be isolated and later combined with the polymeric material in a melt. The invention encompasses a variety of wood derivatives, composites, and nanocomposites useful for preparing multiple types of products, including membranes, fibers, and formed parts.

A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or 0-acyl isourea, or both N-acylurea and 0-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.

The invention provides a method for screening stereoselective alpha-hydroxy acid dehydrogenase, comprising the following steps: (1) dissolving a sample to be detected containing alpha-hydroxy acid dehydrogenase in a buffer with pH of 6-9, adding an alpha-hydroxy acid chiral monomer as a substrate, and carrying out conversion reaction in water-bath at 20-50 DEG C; and (2) after the conversion reaction, adding the conversion solution in an FeCl3 developer solution to conduct color development reaction for 5-30 min, when the color development reaction finishes, judging the result according to the color appeared in the reaction solution. The method has no need to carry out derivatization on the substrate which is intend to screen, can rapidly identify the dehydrogenase activity and optical selectivity of the selected microbe by using simple colourimetry, has the advantages of simple screening flow, fast speed, low request for devices, strong versatility and the like, and offers great conveniences to the obtainment of optically pure products by using racemic mandelic acid and related derivatives as substrates to carry out resolution through biological enzymatic method.

A method for cutting single-wall carbon nanotubes involves partially fluorinating single-wall carbon nanotubes and pyrolyzing the partially fluorinated nanotubes in an inert atmosphere or vacuum up to about 1000° C. The nanotubes are optionally purified before cutting. The partial fluorination involves fluorinating the nanotubes to a carbon-fluorine stoichiometry of CF_x, where x is up to about 0.3. The invention also relates to the derivatization of fluorinated and cut single-wall carbon nanotubes. The single-wall carbon nanotubes can be cut to any length depending on the fluorination and pyrolysis conditions. Short nanotubes are useful in various applications, such as field emitters for flat panel displays and as “seeds” for further nanotube growth.

The invention relates to methods for modulating the side effects, including immunogenicity, of a protein therapeutic via derivatization with a protein protecting group using reversible or labile linkages.

The present invention provides binding assays, referred to here as fluorescence proximity assays or FPA. The inventions detect binding of target molecules in a sample to a molecular probe or probes that specifically bind or hybridize to those molecules. In particular, the molecular probes are immobilized to a bead or particle, such as colloidal gold, the reflects fluorescent energy from a fluorophore. The derivatized beads are contacted to a sample of fluorescently labeled target molecules, and binding of the target is indicated by an increase in the fluorescent signal. Kits are also provided that contain materials and reagents to performing a fluorescence proximity assay.

The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.

The present invention is directed to a bioactive probe or chip (BC) that allows for the isolation of analytes, such as biomolecules, followed by modification or bioreaction on these said analytes. More specifically, the present invention relates to various methods and apparatuses that include the BC and further include characterization and identification technologies, such as Bioactive Chip Mass Spectrometry (BCMS). Within the context of the present invention, BC provides a method and device for the capture and subsequent modifying, such as digestion or derivatization, of an analyte. Further, real-time information regarding a variety of molecular interactions may be provided by techniques such as interaction analysis (IA). Finally, the variety of molecules are localized and concentrated thereby aiding in the identification and/or quantification of the molecules by techniques such as mass spectroscopy. In one embodiment, a method for performing the modification, or bioreaction, of biomolecules is disclosed. Preferably, the method involves capturing an analyte present within a sample by an interactive surface layer located in a separation site; washing unwanted portions of the sample from the surroundings of the captured analyte; transferring the captured analyte from the separation site to a modifying site; modifying or bioreacting the analyte to create a modified or bioreacted analyte. The modified analyte may then be subsequently characterized and/or identified by techniques such as mass spectrometry.

The present invention relates to a purified, easily produced poly-beta-1->4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a beta-1->4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.

One embodiment of the present invention provides a method of treating guar splits comprising exposing guar splits to a treatment chemical to create treated guar splits; and then, without first washing the treated guar splits, grinding the treated guar splits; and, then drying the ground, treated guar splits. Another embodiment of the present invention provides a method of treating a portion of a subterranean formation comprising providing a treatment fluid comprising a viscosifying agent wherein the viscosifying agent comprises ground, treated guar splits made by the following method: exposing guar splits to a treatment chemical to create treated guar splits; and then, without first washing the treated guar splits, grinding the treated guar splits; and, then drying the ground, treated guar splits; placing the treatment fluid into a portion of a subterranean formation.

The invention provides a high-sensitivity and high-throughput kit for simultaneous quantitative detection of 30 amino acids and a preparation method thereof. According to the kit, after extraction treatment of amino acids in a complex sample by using organic solvents, precipitating by using methanol, adding stable isotope-labeled amino acid internal labels, performing derivatization treatment by using hydrochloric acid and n-butanol, drying and redissolving, carrying out reversed-phase chromatography gradient separation by adopting C18 bonded phase silica gel as a stationary phase and acetonitrile-water containing heptafluorobutyric acid and formic acid as a mobile phase, and carrying out quantitative detection by adopting a mass spectrometer. The kit of the invention has the advantages that detection sensitivity can reach 10ng/ml, and all methodological indexes can meet the requirements of quantitative detections of amino acids in clinical examinations, industrial productions and scientific researches.

An inkjet ink is provided that employs one or more water-soluble colorants or water-insoluble colorants, such as solvent dyes, disperse dyes, or pigments. The colorant, whether water-soluble or water-insoluble, is derivatized with one or more crown ethers to render the water-insoluble colorants soluble in water and in water-miscible organic solvents commonly employed in inkjet printing, particularly thermal inkjet printing, and to impart improved properties to the colorants, such as lightfastness, smearfastness, and waterfastness. The inkjet ink comprises a vehicle and at least one crown ether derivatized colorant. The resulting inkjet ink evidences improved print quality properties, compared to inkjet inks containing colorants that are not so derivatized.

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Azlactone-functional supports are used to provide cell selection from a mixture such as bone marrow or peripheral blood having a desired target cell population. An azlactone-functional support is derivatized by covalently coupling to the support a biologically active substance that binds the target cells. A mixture containing the target cells is contacted with the derivatized support to bind the target cells to the biologically active substance, and unbound remaining mixture is removed from the support. Bound cells may be eluted from the support to obtain purified target cells. Biologically active substances include antibodies, lectins, proteins, antigens and avidin. The biologically active substance may directly or indirectly bind cells in the mixture. Indirect binding may be through a second, intermediary biologically active substance that is bifunctional. The azlactone-functional support is provided by incorporating an azlactone moiety into a base polymer support that has been selected by prescreening base polymer supports with a cell mixture to identify a base polymer support having minimal nonspecific binding of cells in the mixture.

A method for detecting secondary metabolites in fresh tobacco leaves by using a derivatization GC-MS (Gas Chromatography-Mass Spectrometer) is characterized by comprising the steps: quickly collecting new tobacco leaves and quickly freezing the new tobacco leaves by using liquid nitrogen on the site, crushing the tobacco leaves after removing the moisture in the tobacco leaves by means of freeze drying, extracting the secondary metabolites from tobacco powder by using a solvent, drying the extracted liquid supernatant, then performing oximation reaction and silane derivatization on the dried extractive, and finally performing analysis by the GC-MS. The method has the prominent advantages that firstly, a method suitable for extracting the secondary metabolites in the fresh tobacco leaves is developed. As the area of the tobacco leaves is larger, the secondary metabolites are not uniformly distributed in the whole tobacco leaves, and the tobacco leaves are not applicable to the punching sampling technique. However, according to a tobacco leave collection and extraction method provided by the invention, the collection period and the metabolite composition of the tobacco leaves at the collected part can be truly reflected. Secondly, most of the important metabolites of the tobacco leaves such as saccharides, amino acids, organic acids, terpene alcohols in the fresh tobacco leaves can be simultaneously detected, and the method has the characteristics of high throughput detection.